These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10891458)

  • 21. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy.
    Benito JM; López M; Lozano S; Ballesteros C; Martinez P; González-Lahoz J; Soriano V
    J Acquir Immune Defic Syndr; 2005 Apr; 38(4):373-81. PubMed ID: 15764953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lymphocytes proliferate in blood and lymph nodes following interleukin-2 therapy in addition to highly active antiretroviral therapy.
    Hengge UR; Borchard C; Esser S; Schröder M; Mirmohammadsadegh A; Goos M
    AIDS; 2002 Jan; 16(2):151-60. PubMed ID: 11807298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease.
    Mezzaroma I; Carlesimo M; Pinter E; Alario C; Sacco G; Muratori DS; Bernardi ML; Paganelli R; Aiuti F
    AIDS; 1999 Jul; 13(10):1187-93. PubMed ID: 10416521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
    García F; Plana M; Vidal C; Cruceta A; O'Brien WA; Pantaleo G; Pumarola T; Gallart T; Miró JM; Gatell JM
    AIDS; 1999 Jul; 13(11):F79-86. PubMed ID: 10449278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.
    Schapiro JM; Winters MA; Stewart F; Efron B; Norris J; Kozal MJ; Merigan TC
    Ann Intern Med; 1996 Jun; 124(12):1039-50. PubMed ID: 8633817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.
    Autran B; Carcelain G; Li TS; Blanc C; Mathez D; Tubiana R; Katlama C; Debré P; Leibowitch J
    Science; 1997 Jul; 277(5322):112-6. PubMed ID: 9204894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma.
    Powles T; Imami N; Nelson M; Gazzard BG; Bower M
    AIDS; 2002 Mar; 16(4):531-6. PubMed ID: 11872995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid plasma virus and CD4+ T-cell turnover in HIV-1 infection: evidence for an only transient interruption by treatment.
    Stellbrink HJ; Zöller B; Fenner T; Lichtenberg G; van Lunzen J; Albrecht H; Thiele HG; Greten H
    AIDS; 1996 Jul; 10(8):849-57. PubMed ID: 8828742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells.
    Kostense S; Otto SA; Knol GJ; Manting EH; Nanlohy NM; Jansen C; Lange JM; van Oers MH; Miedema F; van Baarle D
    Eur J Immunol; 2002 Apr; 32(4):1080-9. PubMed ID: 11920575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.
    Deeks SG; Barbour JD; Grant RM; Martin JN
    AIDS; 2002 Jan; 16(2):201-7. PubMed ID: 11807304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of immune complexes and plasma viral load with CD4+ cell depletion, CD8+ DR+ and CD16+ cell counts in HIV+ hemophilia patients. Implications for the immunopathogenesis of HIV-induced CD4+ lymphocyte depletion.
    Daniel V; Süsal C; Weimer R; Zimmermann R; Huth-Kühne A; Opelz G
    Immunol Lett; 2001 Mar; 76(2):69-78. PubMed ID: 11274723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy.
    Dalod M; Dupuis M; Deschemin JC; Sicard D; Salmon D; Delfraissy JF; Venet A; Sinet M; Guillet JG
    J Virol; 1999 Sep; 73(9):7108-16. PubMed ID: 10438796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The independent effect of drug resistance on T cell activation in HIV infection.
    Hunt PW; Deeks SG; Bangsberg DR; Moss A; Sinclair E; Liegler T; Bates M; Tsao G; Lampiris H; Hoh R; Martin JN
    AIDS; 2006 Mar; 20(5):691-9. PubMed ID: 16514299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early T-cell apoptosis and Fas expression during antiretroviral therapy in individuals infected with human immunodeficiency virus-1.
    Aries SP; Weyrich K; Schaaf B; Hansen F; Dennin RH; Dalhoff K
    Scand J Immunol; 1998 Jul; 48(1):86-91. PubMed ID: 9714415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease.
    Al-Harthi L; Siegel J; Spritzler J; Pottage J; Agnoli M; Landay A
    AIDS; 2000 May; 14(7):761-70. PubMed ID: 10839583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo.
    Sloand EM; Kumar PN; Kim S; Chaudhuri A; Weichold FF; Young NS
    Blood; 1999 Aug; 94(3):1021-7. PubMed ID: 10419894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protease inhibitor and triple-drug therapy: cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatment.
    Chougnet C; Fowke KR; Mueller BU; Smith S; Zuckerman J; Jankelevitch S; Steinberg SM; Luban N; Pizzo PA; Shearer GM
    AIDS; 1998 Dec; 12(18):2397-406. PubMed ID: 9875577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kinetics of the T-cell receptor CD4 and CD8 V beta repertoire in HIV-1 vertically infected infants early treated with HAART.
    Romiti ML; Cancrini C; Castelli-Gattinara G; Di Cesare S; Ciaffi P; Bernardi S; De Gasperi MR; Halapi E; Rossi P
    AIDS; 2001 Nov; 15(16):2075-84. PubMed ID: 11684926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nucleoside-free boosted double PI regimen: significant CD4+ T-cell recovery in patients with poor immunologic response despite virologic suppression.
    Lehmann C; Jung N; Hofmann A; Cornely OA; Wyen C; Fätkenheuer G; Hartmann P
    Curr HIV Res; 2008 Nov; 6(6):555-9. PubMed ID: 18991621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.